{"id":"W2490755617","doi":"10.1182/blood.v126.23.4227.4227","title":"Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"","keywords":"Ixazomib; Medicine; Urology; Hemodialysis; Pharmacokinetics; Dosing; Cmax; Multiple myeloma; Dialysis; Renal function; Pharmacology; Internal medicine; Pharmacodynamics; End stage renal disease; Surgery; Proteasome inhibitor; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007732571,0.0007241343,0.00145926,0.0002499986,0.0003369136,0.000818773,0.0003991077,0.0005477374,0.003416811],"category_scores_gemma":[0.0006731315,0.0004472709,0.0008970709,0.0003180875,0.000568909,0.0005289128,0.0002927364,0.00222156,0.0006092921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00076463,"about_ca_system_score_gemma":0.001214285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005136097,"about_ca_topic_score_gemma":0.001298925,"domain_scores_codex":[0.9997137,0.0001052166,0.00001438245,0.00006842949,0.00004752048,0.0000505905],"domain_scores_gemma":[0.9996339,0.00003401202,0.000102322,0.00002912059,0.00003002487,0.0001705771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5767779,0.117969,0.02953107,0.001351764,0.001917072,0.0005301927,0.0005299195,0.004104029,0.1121311,0.0005049176,0.005941221,0.1487118],"study_design_scores_gemma":[0.1442641,0.7801136,0.05488879,0.0000661454,0.0007512104,0.0008301917,0.0001179417,0.002324765,0.00914824,0.0004016977,0.007040245,0.00005311136],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949398,0.001170643,0.0004572202,0.0001606764,0.00003921869,0.001376677,0.0008487665,0.00004316628,0.0009638444],"genre_scores_gemma":[0.9922247,0.001074078,0.001140228,0.0005260875,0.00005741755,0.001310492,0.001408553,0.00001601169,0.002242476],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003416811,"threshold_uncertainty_score":0.01143038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03441198321908557,"score_gpt":0.2973784338222597,"score_spread":0.2629664506031741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}